A number of trials will test emerging CRISPR therapies in 2022.
Source
Verdict
persistedThe same trend is listed again within the publisher's next two editions (D33). Same subject listed again in 2023.
A trend is graded on whether the publisher keeps it, never as a hit or a miss (D6, D33).
The same forecast in other editions
All captured fields
- rank
- 450
- section
- Synthetic Biology, Biotechnology & AgTech
- subsection
- Synthetic Biology / CRISPR Technologies
- subject
- CRISPR Therapies
- horizon
- Informs Strategy
- page
- 552
- confidence
- high
- note
- horizon is the label the page header highlights (Watch Closely / Informs Strategy / Act Now); it applies to the page the trend starts on.